Oxford Gene Technology Ltd. Featured in The Sunday Times Biotech Supplement

Oxford, UK – 21st January 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, was featured in this week’s edition of the UK weekly broadsheet, The Sunday Times (16th of January, 2011). As part of a pullout focusing on recent developments in life sciences and biotechnology, the article, entitled ‘Better diagnosis, less cost’, describes how OGT’s recent innovations in the fields of biomarker discovery and chromosome analysis will help push healthcare costs down, while improving the accuracy of early disease diagnosis. In a proof-of-principle case study, protein markers that correctly indicated the presence of prostate cancer with over 90% accuracy were identified using OGT’s biomarker discovery technology. As well as protein based screens, OGT employs its expertise in the design of DNA microarrays to improve genetic tests for developmental delay and other unexplained genetic abnormalities. This is achieved using OGT’s CytoSure™ arrays and software, which deliver a five-fold improvement in accuracy over traditional karyotyping techniques when used to detect genetic aberrations. To read the full article, visit www.ogt.co.uk/go/sundaytimes.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF

T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk

W: www.ogt.co.uk

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

CytoSure™: For research use only

This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.